Ambulatory Infusion Pump Open-Loop Fallback for CGM Failures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ambulatory infusion pumps face risks in automatically dosing medicaments like insulin based on potentially inaccurate or unreliable CGM readings, which can lead to dangerous blood glucose level fluctuations.
Innovation Solution
The infusion pump system automatically reverts to open-loop therapy using a stored default basal rate profile and tracks insulin on board, ensuring safe medicament delivery when errors occur in closed-loop operation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If the pump operates in closed-loop mode using CGM readings to automatically adjust medicament delivery, then automation and responsiveness are improved, but reliability deteriorates due to potential CGM inaccuracies
Solution Approach 1:
The patent introduces an intermediary safety layer between the CGM readings and the actual medicament delivery. This includes multiple verification mechanisms such as checking CGM signal quality, validating glucose level plausibility, and requiring confirmation before automatic dosing adjustments. This intermediary layer filters out potentially inaccurate CGM data while preserving beneficial automatic dosing functionality.
Solution Approach 2:
The system performs preliminary validation of CGM readings before using them for automatic dosing decisions. This includes pre-checking sensor functionality, verifying glucose level ranges, and assessing data consistency trends. By performing these preliminary actions, the system prevents unreliable data from triggering incorrect automatic dosing adjustments.
2Productivity
If the pump continuously monitors and automatically adjusts medicament delivery based on CGM data, then treatment effectiveness is improved, but risk of harmful effects increases due to CGM failures
Solution Approach 1:
The patent implements preliminary anti-action by establishing safety constraints and boundaries before automatic dosing can occur. This includes setting minimum and maximum glucose level thresholds, defining maximum dosing adjustment limits, and requiring stable CGM signal conditions. These preliminary protective measures prevent harmful blood glucose fluctuations even when CGM readings are inaccurate.
Solution Approach 2:
The system incorporates multiple feedback mechanisms to detect and respond to CGM failures. This includes monitoring CGM signal quality continuously, comparing trends across multiple readings, and providing alerts when data reliability is compromised. When feedback indicates CGM failure, the system automatically suspends automatic dosing adjustments while maintaining safe baseline delivery, preventing harmful effects.
3Ease of operation
If the pump relies on CGM readings for automatic dosing, then ease of operation is improved, but device complexity increases due to error handling requirements
Solution Approach 1:
The patent implements self-service by enabling the pump to automatically detect CGM failures and autonomously switch between closed-loop and open-loop modes without requiring user intervention. The system self-monitors CGM signal quality, self-diagnoses data reliability issues, and self-adjusts operational mode accordingly. This maintains ease of operation while managing complexity through automated error handling.
Solution Approach 2:
The system dynamically adapts its operational complexity based on CGM reliability. When CGM data is reliable, the system operates in simplified closed-loop mode with full automatic dosing. When CGM failures are detected, the system dynamically transitions to open-loop mode with reduced automation but enhanced safety monitoring. This dynamic adaptation optimizes the balance between ease of operation and error handling complexity.
Data Source
AI summary
An infusion pump system providing therapy to a patient in a closed-loop or semi-closed loop mode can safely automatically revert to open-loop therapy. The system stores a default open- loop basal rate profile in memory. The system also continually tracks the insulin on board for the patient over a plurality of closed-loop therapy intervals. When an error or event occurs requiring reversion to open-loop therapy, the system automatically provides therapy according to the open- loop basal rate profile and the tracked insulin on board amount.